What the FDA labels say about taking them together
Erlotinib and ramucirumab
Ramucirumab's FDA label of June 9, 2026 names erlotinib in its warnings and precautions section; the erlotinib label PlainMeds reads does not name ramucirumab.
Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the ramucirumab FDA label on DailyMed (effective June 9, 2026, Eli Lilly and Company).
What does the erlotinib label say about ramucirumab?
Erlotinib's label (effective June 10, 2024) does not name ramucirumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed
What does the ramucirumab label say about erlotinib?
Ramucirumab label, warnings and precautionsIn 221 patients with NSCLC receiving CYRAMZA in combination with erlotinib in the RELAY study, the incidence of new or worsening hypertension was higher (45%), as was the incidence of Grade 3-5 hypertension (24%).
Source: FDA drug label (CYRAMZA), Eli Lilly and Company, effective June 9, 2026 (SPL set c6080942-dee6-423e-b688-1272c2ae90d4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erlotinib | Ramucirumab | |
|---|---|---|
| Labeled for | Lung cancer | Lung cancer, Colorectal cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once